Potential first-in-class

Discover the landscape of Potential first-in-class in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Potential first-in-class, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis
CompanyDrug

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

Ascletis Pharma Inc. (HKG: 1672) announced positive results from a randomized, double‑blind, placebo‑controlled 28‑day proof‑of‑concept clinical trial of ASC50 in U.S. patients with mild‑to‑moderate plaque psoriasis. ASC50 is an in‑house…

CSPC's SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

CSPC’s SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

Novo Nordisk Licenses Hengrui's HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Novo Nordisk Licenses Hengrui’s HRS‑1596 in Up to USD 2.6 Billion Global Deal – Once‑Weekly Oral Candidate for Obesity and Type 2 Diabetes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers

CompanyDrug

Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363

CompanyDrug

Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer

CompanyDrug

Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China

CompanyDrug

Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment

CompanyDrug

Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention

CompanyDrug

Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study

CompanyDeals

Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m

Show More